Literature DB >> 15330201

Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer.

Daisuke Ichikawa1, Hiroshi Koike, Hisashi Ikoma, Daito Ikoma, Nobuyuki Tani, Eigo Otsuji, Kazuya Kitamura, Hisakazu Yamagishi.   

Abstract

BACKGROUND: This study aimed to detect hypermethylation in serum DNA from patients with gastric cancer at various stages and to assess the assay for early detection of primary and recurrent disease.
MATERIALS AND METHODS: Preoperative serum samples were obtained from 109 patients with gastric cancer. Blood samples were subjected to methylation-specific polymerase chain reaction analysis to determine the methylation status of the promoter region of the p16 and E-cadherin genes.
RESULTS: Forty patients (37%) showed hypermethylation of the promoter region in one or both genes (p16, 20 patients; E-cadherin, 26 patients). Of 36 patients with early-stage gastric cancers, 10 (28%) showed aberrant methylated signals. No aberrant methylation was detected in the serum DNA from 10 healthy volunteers.
CONCLUSION: Aberrant promoter hypermethylation may prove useful as a new serum marker for gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15330201

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  16 in total

Review 1.  DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer.

Authors:  Yuji Toiyama; Yoshinaga Okugawa; Ajay Goel
Journal:  Biochem Biophys Res Commun       Date:  2014-08-13       Impact factor: 3.575

2.  Role of p16 gene promoter methylation in gastric carcinogenesis: a meta-analysis.

Authors:  He-Ling Wang; Ping-Yi Zhou; Peng Liu; Yu Zhang
Journal:  Mol Biol Rep       Date:  2014-03-08       Impact factor: 2.316

3.  Detection of aberrant hypermethylated spastic paraplegia-20 as a potential biomarker and prognostic factor in gastric cancer.

Authors:  Hao Zhang; Yongchun Song; Peng Xia; Yao Cheng; Qi Guo; Dongmei Diao; Wei Wang; Xuandi Wu; Di Liu; Chengxue Dang
Journal:  Med Oncol       Date:  2014-01-01       Impact factor: 3.064

Review 4.  Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications.

Authors:  Keishi Yamashita; Shinichi Sakuramoto; Masahiko Watanabe
Journal:  Surg Today       Date:  2010-12-30       Impact factor: 2.549

Review 5.  DNA methylation based biomarkers in non-invasive cancer screening.

Authors:  N Shivapurkar; A F Gazdar
Journal:  Curr Mol Med       Date:  2010-03       Impact factor: 2.222

6.  HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study.

Authors:  Katsutoshi Shoda; Kiyoshi Masuda; Daisuke Ichikawa; Tomohiro Arita; Yuko Miyakami; Miki Watanabe; Hirotaka Konishi; Issei Imoto; Eigo Otsuji
Journal:  Gastric Cancer       Date:  2014-10-17       Impact factor: 7.370

7.  Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma.

Authors:  H Takeshita; D Ichikawa; S Komatsu; M Tsujiura; T Kosuga; K Deguchi; H Konishi; R Morimura; A Shiozaki; H Fujiwara; K Okamoto; E Otsuji
Journal:  Br J Cancer       Date:  2010-04-13       Impact factor: 7.640

Review 8.  Liquid biopsy of gastric cancer patients: circulating tumor cells and cell-free nucleic acids.

Authors:  Masahiro Tsujiura; Daisuke Ichikawa; Hirotaka Konishi; Shuhei Komatsu; Atsushi Shiozaki; Eigo Otsuji
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

9.  The prognostic significance of whole blood global and specific DNA methylation levels in gastric adenocarcinoma.

Authors:  Mansour S Al-Moundhri; Maryam Al-Nabhani; Letizia Tarantini; Andrea Baccarelli; Jennifer A Rusiecki
Journal:  PLoS One       Date:  2010-12-23       Impact factor: 3.240

10.  Control of carry-over contamination for PCR-based DNA methylation quantification using bisulfite treated DNA.

Authors:  Reimo Tetzner; Dimo Dietrich; Juergen Distler
Journal:  Nucleic Acids Res       Date:  2006-11-28       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.